As part of our ongoing program of random screening to search for new pharmacophores as antitumor agents, we discovered that the known pyrazole derivatives 1-8, 1) 13d-e, 2) which have been prepared as neuroleptics, 3) and a new propanone derivative 13b showed moderate in vitro cytotoxic activity (Table 1) . Encouraged by this result, we synthesized novel compounds based on this scaffold and explored their potential as chemotherapeutic agents by investigating their activity in P-glycoprotein-mediated multidrug-resistant cells and a solid tumor model. In this report, we describe in detail the synthesis of these novel 4-substituted 1-(pyrimidinyl)-pyrazole derivatives and their profile of antitumor activity.
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Chemistry The new substituted piperazine 11a was prepared from aniline derivative 9 and bis(2-chloroethyl)amine hydrochloride (10). Pyrimidinyl pyrazole propanone derivatives 13a-c were prepared by Mannich reaction of acetyl pyrazoles 12a and 12b 2) with suitably substituted phenyl piperazines 11a-c in the presence of paraformaldehyde. These propanone derivatives 13a-c and known derivatives 13d-i 2) were reduced with NaBH 4 and dehydrated in the presence of p-toluenesulfonic acid (p-TsOH) to give propene derivatives 14a-i. Demethylation of 13c and 13i by treatment with BBr 3 gave 15a and 15b, respectively. Propanones 15a and 15b were converted to the propene derivatives 16a and 16b using the same procedure as for the preparation of 14 from 13. Compound 18 without a pyrimidine substituent was derived from 13i by hydrolysis with 47% HBr, reduction with NaBH 4 , and dehydration by p-TsOH, because the bond between the pyrazole and pyrimidine rings was easily cleaved by strong acid. Compounds 24a-c bearing a bulky substituent in the R 7 or R 8 position were prepared starting from diketones 19a-c. The compounds 19a-c were treated with CH(OEt) 3 and Ac 2 O, and cyclized with pyrimidinyl hydrazine 20 2) to give ketones 21a-c. Compound 21c was used in the following step as a mixture with 4-benzoyl-1-(2-pyrimidinyl)-5-methylpyrazole (22) without purification. The ketones 21a-c were treated with 1-(3-chlorophenyl)piperazine · HCl (11c) to obtain propanone derivatives 23a-c, which were reduced by NaBH 4 , and dehydrated as described above to give 24a-c.
Biological Activity and Structure-Activity Relationship (SAR) Studies The cytotoxic activity (GI 50 values) of randomly screened compounds against P388 leukemia cells and PC-6 human lung carcinoma cells is shown in Table 1 . 5-Fluorouracil (5-FU) was used as a reference compound. Known methylene derivatives 1-8 1) and propanone derivatives 2) 13b, d, e showed only weak or moderate in vitro cytotoxic activity. The derivatives 2, 5, and 8 bearing a longer chain (CH 2 ) 3 showed more potent activity than the derivatives bearing CH 2 or (CH 2 ) 2 . When the number of carbon atoms in the methylene group was three, the activity of the propanones 13b, d, e was clearly better than that shown by the propane type 2, 5, and 8, respectively. Furthermore, propene derivatives 14b, d, e showed enhanced activity compared with the corresponding propanones 13b, d, e (Table 2 ). This encouraging trend was pursued by synthesizing further derivatives with a vinyl group. The effect on activity of changing substituents in the phenyl ring was also investigated. Compounds 14b and 14f bearing a halogen atom at the o-position of the phenyl ring showed potent in vitro cytotoxic activity compared with the o-methyl derivative 14e, while the activity of non-substituted derivative 14d was similar to that of 14e.
The m-chloro derivative 14g showed similar and potent activity to that of o-chloro derivative 14f, but the p-fluoro substituent of 14h dramatically decreased the in vitro activity. 4-Methyl-6-methoxypyrimidine 14i showed decreased activity while 4-methyl-6-hydroxypyrimidine 16b retained activity. The pyrimidine ring is important for activity, because the activity of 18 without a pyrimidine substituent is considerably lower than 14e. Introduction of a bulky group in the pyrazole 5-position and/or vinyl moiety caused a decrease in cytotoxic activity (24a-c).
The in vivo antitumor activity of compounds 14b, d-g, which showed strong cytotoxic activity in vitro, was evaluated against murine P388 leukemia by intraperitoneal administration. The observed percentage of increase in life span (ILS) is shown in toxic activity in vitro, only slightly prolonged life span. The halogen-substituted derivatives 14b, f-g significantly enhanced longevity compared with 14d and 14e. Thus, there appears to be a close correlation between in vitro cytotoxic activity and in vivo antitumor activity. Among these compounds, the m-chloro derivative 14g exhibited the most potent antitumor effect in vivo with an ILS value of 69%, very similar to that of 5-FU.
The appearance of drug resistant cells in patients is known to be one of the biggest obstacles when antitumor agents are used for chemotherapy.
4) Therefore, the activity of 14g was also evaluated in the multidrug resistant (MDR) cell lines PC-6/VCR 5) and SBC-3/ADM, 6) which have been reported to overexpress P-glycoprotein. The extent of activity against resistant cell lines compared with the parent cell line is shown by the resistance rate (Table 3) . Although adriamycin (ADM) and vincristine (VCR) showed high cross-resistance, 14g did not show significant cross-resistance, as indicated by the rates of 1.0 and 1.42, respectively, against the two cell lines. The tumor growth-inhibition rate (IR) of 14g was also evaluated both intraperitoneally (i.p.) and orally (p.o.) against a solid tumor Meth A mouse fibrosarcoma (Table 4 ). The activity of 5-FU (IRmaxϭ26.0% (i.p.) and 40.3% (p.o.), respectively) was weak in spite of the considerable body weight losses of 9.2% and 14.5%. Compound 14g exhibited potent antitumor activity with IR values of 62.1% (43ϫ5 mg/kg, i.p.) and 88.2% (60ϫ5 mg/kg, p.o.), and was superior to 5-FU. This result suggests that 14g is well-absorbed. The main side effects observed at these doses were induction of catalepsy and decrease of body temperature without body weight loss.
In conclusion, compound 14g showed potent cytotoxic activity against P388 and PC-6 cancer cell lines including Pglycoprotein-mediated MDR cell lines in vitro and high antitumor activity against a solid tumor when administered orally. The pyrazole derivatives reported here represent a new December 1999 1681 pharmacophore, and have not previously been reported as antitumor agents. Although the muscle relaxation effect associated with catalepsy 7) was observed when 14g was administered to mice, this is understandable. It is for reason that the parent compounds had previously been found to show central nervous system (CNS) effects and to act as tranquilizers. 8) Synthesis of further analogues based on this scaffold to minimize CNS side effects is in progress. Compound 14g was also found to inhibit tubulin polymerization. Detailed studies of the mechanism and action of these compounds on tumor cells will be reported separately.
Experimental
Melting points were determined on a Yanaco MP-500D apparatus and are uncorrected. Infrared (IR) spectra were recorded on a JEOL JIR-5300 or Horiba FT-720 spectrometer.
1 H-NMR spectra were recorded on a JEOL JNM-EX400 (400 MHz) instrument and the chemical shifts are given in d values. The abbreviations used are as follows: s, singlet; d, doublet; t, triplet; q, quartet; dd, doublet of doublet; dt, doublet of triplet; br, broad; m, multiplet. Mass spectra (MS) were recorded on a JEOL JMS-HX110 or a JMS-AX505W mass spectrometer. Elemental analyses were performed using a Perkin-Elmer Series II CHNS/O 2400 instrument. Column chromatography was performed with Silica gel 60 F 254 (70-230 mesh) (Merck). Sodium sulfate was employed as a drying agent. 2) (285 mg, 1.41 mmol), amine 11a (300 mg, 1.20 mmol), and paraformaldehyde (600 mg) in EtOH (30 ml) was heated to reflux, and additional paraformaldehyde (2.4 g) was added in small portions over 24 h. After being stirred for 48 h, the reaction mixture was cooled, and the precipitate obtained was filtered to give 13a (244 mg, 44%). Compounds 11b and 11c were treated with 12a and 12b 2) in the manner described above to give 13b and 13c, respectively. 13a: mp 170-175°C (dec. Pyrimidinylpyrazole Propene Derivatives (14a-i). Illustrative Procedure Sodium borohydride (280 mg, 7.37 mmol) was added in small portions to a solution of 13a (230 mg, 0.50 mmol) in EtOH (10 ml) and tetrahydrofuran (THF) (10 ml). The mixture was stirred at room temperature until TLC indicated completion of the reaction. The reaction mixture was diluted with H 2 O and extracted with CHCl 3 . The organic layer was washed with H 2 O, dried, and evaporated in vacuo. To this residue were added THF (20 ml), dioxane (30 ml), and p-TsOH · H 2 O (170 mg), and the resulting mixture was heated to reflux for 1.5 h. The mixture was diluted with saturated NaHCO 3 solution and extracted with CHCl 3 . The organic layer was washed with H 2 O, dried, and evaporated in vacuo. The residue was chromatographed on silica gel (CHCl 3 -MeOH, 30 : 1), diluted with 1 N HCl/EtOH, and evaporated in vacuo. The residue was recrystallized from EtOH to give 14a (68 mg, 28%). Compounds 13b, c and 13d-i 2) were treated in the manner described above to give 14b-i, respectively. The physical data for these compounds and yields are shown in Table 5 . phenyl)-1-piperazinyl]-1-propanone · HCl (15a) A solution of 13c (950 mg, 2.0 mmol) in CH 2 Cl 2 (150 ml) was added to a solution of BBr 3 (600 mg, 2.4 mmol) in CH 2 Cl 2 (8 ml) at 0°C, and the resulting mixture was stirred at room temperature for 45 h. The mixture was diluted with CH 2 Cl 2 and the organic layer was washed with saturated NaHCO 3 solution and H 2 O, dried, and evaporated in vacuo. The residue was chromatographed on silica gel (CHCl 3 -MeOH, 10 : 1), diluted with 1 N HCl/EtOH and evaporated in vacuo, then was recrystallized from EtOH to give 15a (167 mg, 16%), mp 177-181°C (dec. Hydroxypyrimidinylpyrazole Propene Derivatives (16a-b) Compounds 15a and 15b were treated in the same manner as described for 14a-i to give 16a and 16b, respectively. The physical data for these compounds and yields are shown in Table 5 . Table 5 .
1-(3-Chloro-4-hydroxyphenyl)piperazine · HCl (11a)

1-[5-Methyl-1-(4-hydroxy-2-pyrimidinyl)-4-pyrazolyl]-3-[4-(3-chloro
5-Ethyl-4-propionyl-1-(2-pyrimidinyl)pyrazole (21a) A mixture of 3,5-heptadione (19a) (5.11 g, 39.9 mmol) and triethyl orthoformate (7.96 ml, 47.9 mmol) in Ac 2 O (4.52 ml, 47.9 mmol) was heated to reflux for 50 min. After removal of the solvent, the residue was distilled at 117-125°C under 4 mmHg to give 4-ethoxymethylene-3,5-heptadione (3.0 g, 41%) as an oil. 1 (20) 2) (0.941 g, 8.55 mmol) in EtOH (11 ml) was stirred at 60°C for 3 h. After removal of the solvent, the residue was chromatographed on silica gel (AcOEt-hexane, 1 : 1) to give 21a (1.49 g, 79%) as an oil. 4-Acetyl-5-benzyl-1-(2-pyrimidinyl)pyrazole (21b) A mixture of 1-phenyl-2,4-pentadione (19b) (10 g, 56.7 mmol) and triethyl orthoformate (14.2 ml, 85.1 mmol) in Ac 2 O (16.1 ml, 170 mmol) was heated to reflux for 1 h. After removal of the solvent, the residue was chromatographed on silica gel (AcOEt-hexane, 2 : 1) to give 3-hydroxymethylene-1-phenyl-2,4-pentadione (7.34 g, 63%) as an oil. 4-Acetyl-5-phenyl-1-(2-pyrimidinyl)pyrazole (21c) A mixture of 1-phenyl-1,3-butanedione (19c) (10 g, 61.7 mmol) and triethyl orthoformate (5.26 ml, 61.7 mmol) in Ac 2 O (11.6 ml, 123 mmol) was heated to reflux for 50 min. After removal of the solvent, the residue was chromatographed on silica gel (AcOEt-hexane, 1 : 3) to give 2-ethoxymethylene-1-phenyl-1,3-butanedione (3.23 g, 24% Pyrimidinylpyrazole Propene Derivatives (24a-c) Compounds 23a, 23b, and 23c were treated in the manner described for 14a to give 24a, 24b, and 24c, respectively. The physical data for these compounds and yields are shown in Table 5 .
In Vitro Cytotoxicity To examine the direct growth-inhibitory effects of test compounds against PC-6 human non-small cell lung cancer cell line, SBC-3 human small cell lung cancer cell line, these resistant cell lines (PC-6/VCR 5) , SBC-3/ADM 6) ), and P388 murine leukemia cell line, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was performed and the concentration giving a growth inhibition of 50% (GI 50 ) was calculated according to the published procedure. 5) Evaluation of Therapeutic Effect in Vivo P388 cells (1ϫ10 6 ) were inoculated i.p. into CDF1 mice (6 mice per group) on day 0. Compounds and 5-FU were suspended in BTC salt solution (0.9% benzyl alcohol, 0.4% Tween 80, 0.5% carboxymethyl cellulose, 0.9% NaCl) and given i.p. on days 1 and 5. The ILS was calculated using the following formula: ILS (%)ϭ [(median survival time of treated group)/(median survival time of control group)-1]ϫ100. Meth A murine fibrosarcoma cells (1ϫ10 6 ) were implanted into the right flank of BALB/c mice (day 0). Compound 14g and 5-FU were administered i.p. or p.o. on days 7-11 consecutively. Tumor weights were measured on day 17. The IR was calculated using the formula: IR (%)ϭ(1-TWt/TWc)ϫ100 (%), where TWt represents the mean tumor weight of a treated group and TWc represents that of the control group. To evaluate the intensity of the side effects of compounds, the rate of body weight loss (BWL) was utilized as a parameter of toxicity. The maximum value of BWL was designated as BWLmax, and BWLmax less than zero indicated no body weight loss.
